accountthis year By Bill Berkrot NEW YORK, May 18 (Reuters) - A drug for advanced kidney cancer from Pfizer Inc (PFE.N The drug, axitinib, extended progression-free survival, or the time it took for the disease to worsen, by 6.7 months compared with 4.7 months...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pfizer kidney cancer drug effective in key study
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account